164 related articles for article (PubMed ID: 22575865)
1. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.
Walts AE; Ines D; Marchevsky AM
Mod Pathol; 2012 Sep; 25(9):1258-64. PubMed ID: 22575865
[TBL] [Abstract][Full Text] [Related]
2. The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors.
Dermawan JKT; Farver CF
Am J Surg Pathol; 2020 Feb; 44(2):224-231. PubMed ID: 31490236
[TBL] [Abstract][Full Text] [Related]
3. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.
Swarts DR; Rudelius M; Claessen SM; Cleutjens JP; Seidl S; Volante M; Ramaekers FC; Speel EJ
Histopathology; 2017 Feb; 70(3):412-422. PubMed ID: 27701763
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Immunohistochemistry for Ki-67 and OTP on Small Biopsies of Pulmonary Carcinoid Tumors: Ki-67 Index Predicts Progression-free Survival and Atypical Histology.
Naso JR; Jenkins SM; Roden AC; Yi ES; Lo YC; Bois MC; Maleszewski JJ; Aubry MC; Boland JM
Am J Surg Pathol; 2024 Jun; 48(6):742-750. PubMed ID: 38584496
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.
Clay V; Papaxoinis G; Sanderson B; Valle JW; Howell M; Lamarca A; Krysiak P; Bishop P; Nonaka D; Mansoor W
Clin Transl Oncol; 2017 May; 19(5):579-586. PubMed ID: 27848218
[TBL] [Abstract][Full Text] [Related]
6. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.
Laitinen KL; Soini Y; Mattila J; Pääkkö P
Cancer; 2000 Apr; 88(7):1590-8. PubMed ID: 10738217
[TBL] [Abstract][Full Text] [Related]
7. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.
Marchevsky AM; Hendifar A; Walts AE
Mod Pathol; 2018 Oct; 31(10):1523-1531. PubMed ID: 29802361
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
9. [Pulmonary carcinoid: analysis of a single institutional experience and prognostic factors].
Correia Sda S; Pinto C; Bernardo J
Acta Med Port; 2014; 27(6):749-54. PubMed ID: 25641291
[TBL] [Abstract][Full Text] [Related]
10. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor.
Vesterinen T; Mononen S; Salmenkivi K; Mustonen H; Räsänen J; Salo JA; Ilonen I; Knuuttila A; Haglund C; Arola J
Acta Oncol; 2018 Aug; 57(8):1109-1116. PubMed ID: 29463166
[TBL] [Abstract][Full Text] [Related]
12. Interobserver variability for the WHO classification of pulmonary carcinoids.
Swarts DR; van Suylen RJ; den Bakker MA; van Oosterhout MF; Thunnissen FB; Volante M; Dingemans AM; Scheltinga MR; Bootsma GP; Pouwels HM; van den Borne BE; Ramaekers FC; Speel EJ
Am J Surg Pathol; 2014 Oct; 38(10):1429-36. PubMed ID: 25046341
[TBL] [Abstract][Full Text] [Related]
13. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
14. Histomorphometric evaluation of the Ki-67 proliferation rate and CD34 microvascular and D2-40 lymphovascular densities drives the pulmonary typical carcinoid outcome.
de Vilhena AF; das Neves Pereira JC; Parra ER; Balancin ML; Ab Saber A; Martins V; Farhat C; Abrantes MM; de Campos JRM; Tedde ML; Takagaki T; Capelozzi VL
Hum Pathol; 2018 Nov; 81():201-210. PubMed ID: 30031097
[TBL] [Abstract][Full Text] [Related]
15. Distinctive pathological and clinical features of lung carcinoids with high proliferation index.
Marchiò C; Gatti G; Massa F; Bertero L; Filosso P; Pelosi G; Cassoni P; Volante M; Papotti M
Virchows Arch; 2017 Dec; 471(6):713-720. PubMed ID: 28631159
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20.
Kasajima A; Konukiewitz B; Oka N; Suzuki H; Sakurada A; Okada Y; Kameya T; Ishikawa Y; Sasano H; Weichert W; Klöppel G
Neuroendocrinology; 2019; 108(2):109-120. PubMed ID: 30485860
[TBL] [Abstract][Full Text] [Related]
17. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement.
Thomas CF; Tazelaar HD; Jett JR
Chest; 2001 Apr; 119(4):1143-50. PubMed ID: 11296182
[TBL] [Abstract][Full Text] [Related]
18. Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors.
Gasparri R; Rezende GC; Fazio N; Maisonneuve P; Brambilla D; Travaini LL; Paganelli G; Petrella F; Galetta D; Spaggiari L
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):446-54. PubMed ID: 26416036
[TBL] [Abstract][Full Text] [Related]
19. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids.
Warth A; Fink L; Fisseler-Eckhoff A; Jonigk D; Keller M; Ott G; Rieker RJ; Sinn P; Söder S; Soltermann A; Willenbrock K; Weichert W;
Virchows Arch; 2013 May; 462(5):507-13. PubMed ID: 23559305
[TBL] [Abstract][Full Text] [Related]
20. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study.
Costes V; Marty-Ané C; Picot MC; Serre I; Pujol JL; Mary H; Baldet P
Hum Pathol; 1995 Jul; 26(7):740-5. PubMed ID: 7628845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
